低分子肝素钙治疗肺心病并呼吸衰竭的临床影响分析  

Analysis of the Clinical Effects of Low Molecular Weight Heparin Calcium in the Treatment of Pulmonary Heart Disease with Respiratory Failure

作　　者：王玉玲[1] 宋秀婧[1] WANG Yuling;SONG Xiujing(Department of Respiratory and Critical Care Medicine,Qiqihar First Hospital,Qiqihar,Heilongjiang Province,161000 China)

机构地区：[1]齐齐哈尔市第一医院呼吸与危重症医学科,黑龙江齐齐哈尔161000

出　　处：《系统医学》2021年第14期12-15,共4页Systems Medicine

基　　金：齐齐哈尔市科学技术计划项目(SFZD-2019062)。

摘　　要：目的探究低分子肝素治疗肺心病合并呼吸衰竭的临床效果。方法选取2018年10月—2020年12月就诊于该院的肺心病合并呼吸衰竭患者68例,基于随机抽签方式分组法将研究对象分为对照组(34例)与研究组(34例)。对照组对患者施以的方式为常规治疗,研究组在常规治疗基础上联合低分子肝素对患者施以治疗,对两组患者的临床治疗、动脉血气指标等情况进行比较和分析。结果研究组临床治疗总有效率为94.12%,其数据与对照组进行比较差异有统计学意义(χ^(2)=6.476,P<0.05);研究组患者PaCO_(2)、PaO_(2)、pH、全血黏度、血浆黏度以及红细胞沉降率分别为(39.32±1.07)mmHg、(83.29±1.57)mmHg、(7.48±0.13)、(7.23±2.36)mPa·s、(1.97±0.33)mPa·s、(21.14±4.89)mm/h,其数据均显著优于对照组,差异有统计学意义(t=20.735、9.858、3.949、3.531、5.253、4.725,P<0.05)。结论应用低分子肝素对肺心病合并呼吸衰竭患者施以治疗可明显提升临床效果,对于患者动脉血气指标的改善和康复具有积极意义,值得在临床中大力推荐。Objective To explore the clinical effect of low molecular weight heparin in the treatment of pulmonary heart disease with respiratory failure.Methods A total of 68 patients with pulmonary heart disease and respiratory failure diagnosed and treated in the hospital from October 2018 to December 2020 were selected.Based on the random lottery grouping method,the subjects were divided into the reference group(34 cases)and the study group(34 cases),the reference group was given conventional treatment to the patients.The study group combined low-molecular-weight heparin on the basis of conventional treatment to treat the patients.The clinical treatment and arterial blood gas indicators of the two groups were compared and analyzed.Results The total effective rate of clinical treatment in the study group was 94.12%,and the difference was statistically significant compared with the control group(χ^(2)=6.476,P<0.05);the study group patients PaCO_(2),PaO_(2),pH,whole blood viscosity,plasma viscosity and red blood cell sedimentation rates were respectively(39.32±1.07)mmHg,(83.29±1.57)mmHg,(7.48±0.13),(7.23±2.36)mPa·s,(1.97±0.33)mPa·s,(21.14±4.89)mm/h,the data were significantly better than the reference group,the difference were statistically significant(t=20.735,9.858,3.949,3.531,5.253,4.725,P<0.05).Conclusion The application of low-molecular-weight heparin to the treatment of patients with cor pulmonale and respiratory failure can significantly improve the clinical effect,and is of positive significance for the improvement and rehabilitation of patients'arterial blood gas indicators,and is worthy of strong clinical recommendation.

关 键 词：肺心病 呼吸衰竭 低分子肝素 治疗效果 动脉血气指标 

分 类 号：R59[医药卫生—内科学]